scholarly journals Hyperkalemia, Worsening Renal Function, Acute Kidney Injury and Clinical Outcomes in Acute Heart Failure

2019 ◽  
Vol 25 (8) ◽  
pp. S18
Author(s):  
Yu Horiuchi ◽  
Nicholas Wettersten ◽  
Patrick Murray ◽  
Alan Maisel
2015 ◽  
Vol 21 (5) ◽  
pp. 382-390 ◽  
Author(s):  
Gregory Berra ◽  
Nicolas Garin ◽  
Jérôme Stirnemann ◽  
Anne-Sophie Jannot ◽  
Pierre-Yves Martin ◽  
...  

2010 ◽  
Vol 31 (22) ◽  
pp. 2791-2798 ◽  
Author(s):  
J. P. E. Lassus ◽  
M. S. Nieminen ◽  
K. Peuhkurinen ◽  
K. Pulkki ◽  
K. Siirila-Waris ◽  
...  

Renal Failure ◽  
2021 ◽  
Vol 43 (1) ◽  
pp. 123-127
Author(s):  
Chutatip Limkunakul ◽  
Benjawan Srisantithum ◽  
Yotin Lerdrattanasakulchai ◽  
Thanakorn Laksomya ◽  
Jatuphorn Jungpanich ◽  
...  

2021 ◽  
Author(s):  
Toby J L Humphrey ◽  
Glen James ◽  
Eric T Wittbrodt ◽  
Donna Zarzuela ◽  
Thomas F Hiemstra

Abstract Background Users of guideline-recommended renin–angiotensin–aldosterone system (RAAS) inhibitors may experience disruptions to their treatment, e.g. due to hyperkalaemia, hypotension or acute kidney injury. The risks associated with treatment disruption have not been comprehensively assessed; therefore, we evaluated the risk of adverse clinical outcomes in RAAS inhibitor users experiencing treatment disruptions in a large population-wide database. Methods This exploratory, retrospective analysis utilized data from the UK’s Clinical Practice Research Datalink, linked to Hospital Episodes Statistics and the Office for National Statistics databases. Adults (≥18 years) with first RAAS inhibitor use (defined as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) between 1 January 2009 and 31 December 2014 were eligible for inclusion. Time to the first occurrence of adverse clinical outcomes [all-cause mortality, all-cause hospitalization, cardiac arrhythmia, heart failure hospitalization, cardiac arrest, advancement in chronic kidney disease (CKD) stage and acute kidney injury] was compared between RAAS inhibitor users with and without interruptions or cessations to treatment during follow-up. Associations between baseline characteristics and adverse clinical outcomes were also assessed. Results Among 434 027 RAAS inhibitor users, the risk of the first occurrence of all clinical outcomes, except advancement in CKD stage, was 8–75% lower in patients without interruptions or cessations versus patients with interruptions/cessations. Baseline characteristics independently associated with increased risk of clinical outcomes included increasing age, smoking, CKD, diabetes and heart failure. Conclusions These findings highlight the need for effective management of factors associated with RAAS inhibitor interruptions or cessations in patients for whom guideline-recommended RAAS inhibitor treatment is indicated.


Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Jonghanne Park ◽  
Jin Joo Park ◽  
Young-Jin Cho ◽  
Yeon-Yee Yoon ◽  
Il-Young Oh ◽  
...  

Objectives: We investigated the risk factors for contrast-induced acute kidney injury (CIAKI) after coronary angiography (CAG) in patients with acute heart failure (AHF), especially with regard to the volume status. Background: Heart failure is a well-known risk factor for CIAKI after CAG. In HF patients, renal perfusion decreases with systemic congestion. Thus, the standard prevention strategy with isotonic solution infusion may be inappropriate while decongestion may be beneficiary in AHF patients undergoing CAG. Deviation from dry body weight suggests imbalanced volume status. Methods: A total of 199 AHF patients who underwent CAG were eligible for the analysis. Absolute deviation of body weight (


PLoS ONE ◽  
2020 ◽  
Vol 15 (6) ◽  
pp. e0235493
Author(s):  
Kenji Yoshioka ◽  
Yuya Matsue ◽  
Takahiro Okumura ◽  
Keisuke Kida ◽  
Shogo Oishi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document